WNAM REPORT: The opening of the center became an important stage in implementing the investment agreement signed with Tashkent Pharma Park Cluster in November 2022. This center was established according to EU standards for the procurement of plasma as pharmaceutical raw materials to produce appropriate products and meet the country’s needs.A GMP system has been implemented at the Feruza Plasma Center, a set of high-tech equipment and consumables has been purchased in the UK and Italy, leading employees have been trained in the Czech Republic, and GMP standards specialists have been invited from Hungary. The center has received a license for medical activities, a GMP certificate, and a permit to produce blood products such as albumin, immunoglobulins, and blood coagulation factors.It is planned to launch 3 more plasma collection centers in Tashkent and more than 20 in all regions by the end of the year.
Uzbekistan’s New NGO Law: From Control to Partnership
Civil society, often referred to as the backbone of democracy, has long faced suspicion, bureaucratic hurdles, and political pressure in...
